A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Cash from Financing Activities
â‚©1.8B
CAGR 3-Years
39%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash from Financing Activities
-â‚©196.8B
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
-20%
SK Bioscience Co Ltd
KRX:302440
Cash from Financing Activities
-â‚©89.6B
CAGR 3-Years
-288%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash from Financing Activities
-â‚©181.7B
CAGR 3-Years
-91%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Financing Activities
-â‚©17.7B
CAGR 3-Years
-39%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Financing Activities
â‚©32.5B
CAGR 3-Years
-43%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Cash from Financing Activities?
Cash from Financing Activities
1.8B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Cash from Financing Activities amounts to 1.8B KRW.

What is ABL Bio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-52%

Over the last year, the Cash from Financing Activities growth was -56%. The average annual Cash from Financing Activities growth rates for ABL Bio Inc have been 39% over the past three years , -52% over the past five years .

Back to Top